Intravenous Metoprolol in Septic Shock

Alexandria University100 enrolled

Overview

A RCT designed to assess the effect of giving intravenous beta-blockers in patients with septic shock after achieving hemodynamic stability. The principle of this study is to control heart rate allowing for better diastolic filling and thus better perfusion.

A RCT, conducted at alexandria main university hospital, patients were divided into 2 groups, Control group which received the standard care for septic shock and metoprolol group which recieved intravenous metoprolol then patients were assessed for Blood pressure, heart rate, iv fluids needed, vasopressor doses and 28 days mortality

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

100

Conditions

Septic Shock Ventilator Acquired Pneumonia

Interventions

Intravenous metoprolol tartrateDRUG

An intravenous beta-blockers, recieved FDA approval

Standard Care (in control arm)OTHER

Standard care according to surviving sepsis campaign

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The study population included adult patients (≥ 18 years) diagnosed with septic shock secondary to VAP with sinus tachycardia, from April 1, 2022, to April 31, 2023. Septic shock was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). VAP was identified as per the guidelines provided by the American Thoracic Society and Infectious Diseases Society of America. Exclusion Criteria: * Patients were excluded if they had contraindications to beta-blockers, had a history of heart failure, or had been receiving beta-blockers prior to the septic shock. Patients were also excluded if they developed complications from beta- blockers administration.

Locations (1)

Alexandria Main university hospital

Alexandria, Egypt

Outcomes

Primary Outcomes

28-day Mortality

Time frame: 28 days

Secondary Outcomes

ICU stay

Time frame: 28 days

ventilator days

Time frame: 28 days

iv fluids

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.